. 2020 Dec 27;10(1):67. doi: 10.3390/jcm10010067

Table 2.

Changes in outcome measures assessing secondary efficacy variables from baseline (BSL) to the last month of trimester (Τ3) of supplementation with in 113 patients comprising both the efficacy and intention to treat population.

Tools Assessing Secondary Endpoints	BSL	T3	p Value
Tools Assessing Secondary Endpoints	Mean ± SD Median	Mean ± SD Median	p Value
HIT-6	68.6 ± 5.7 69	63.8 ± 10.3 63	p < 0.001
MIDAS	67.0 ± 43.8 58	49.5 ± 41.0 30	p < 0.001
MTAQ	2.9 ± 1.1 3	3.2 ± 0.9 4	p < 0.001
MSQ-QOL total	52.3 ± 15.4 52	71.3 ± 10.4 71	p < 0.001
HADS-A	8.3 ± 5.8 6	8.3 ± 8.5 7	p = 0.923
HADS-D	5.7 ± 3.7 5	6.1 ± 5.2 4	p = 0.216

Abbreviations: Headache Impact Test-6 (HIT 6); Migraine Disability Assessment questionnaire (MIDAS); Migraine Therapy Assessment questionnaire (MTAQ); Migraine-Specific Quality of life questionnaire (MSQ-QOL) and Hospital Anxiety and Depression Scale (HADS) anxiety (A) and depression (D).